...Raised ($M)(a) Tularik 10/11/96 $60.0 Affymetrix 8/3/95 $39.0 Sequenom 4/19/99 $37.0 Medicines Co. 8/31/98 $36.0 Therexsys...

...worth 8 percent of Therexsys' shares outstanding, about £4 million (US$6.8 million), to Cobra's founders. Therexsys...
...Therexsys will change its name to Cobra Therapeutics Ltd. Cobra Biosciences Ltd. , Birmingham, U.K. Therexsys Ltd....

...Therexsys said U.S. Patent No. 5,532,143 issued covering its Locus Control Region (LCR) technology. Therexsys has...
...ensure that the introduced gene is expressed in target cells and not in other cells. Therexsys Ltd....

...Kent, plus Robin Offord and Keith Rose Corporate partners: Icos Corp. , SmithKline Beecham and Therexsys Ltd....

...the vaccine or gene therapy markets only with partners. Grphyon has an ongoing collaboration with Therexsys Ltd....

...the manufacture of gene-based medicines. Therexsys is developing non-viral, targeted and regulated gene delivery systems. Therexsys Ltd....

...to deliver genes successfully is the regulation of expression of the genes in target cells. Therexsys Ltd....
...genes to be transcribed. Thus the LCR technology enables protein expression in specific cells, giving Therexsys...
...of position. Grosveld, now at Erasmus University (Rotterdam), is continuing to collaborate with Therexsys. Self-assembly Therexsys...